3Bacala R,Makita Z,Koschinsky T,et al.Lipid advanced glycosylation:Pathway for tyid ox idation in vivo[J].Proc Natl Acad Sci USA,2002,90:6 364.
4Collier A.Free radial activity in type Ⅱ diabetes[J].Diabetic Med,1998,(7):27-30.
5Festa A.Low-density lipoprotein patritical size INS inversely related to PAI-1 levels[J].Artherioscler Thromb Vascular Biol,1999,19(3):605-610.
6Sobel BE.Increased plasminogen activator type1 in coronary atherectom specimens from type 2 diabetic compared with nondiabetic[J].Circulation,1998,97(22):2 213.
7Burton E,Sobel MD.Increased plasminogen activator inhibitor 1 and vasculopath[J].Circulation,1999,99:2 496.
8Sower JR.Insulin and insulin-like growth factor in moral and pathological vascular physiology[J].Hypertention,1997,29(3):691.
9Fattal PG,Schneider DJ,Sobel BE,et al.Post-transcriptional regulation of expression plasminogen activitor inhibitor type-1 mRNA by insulin and insulin-like growth factor 1[J].Biol Chem,2002,267:12 412-12 415.
10Grant PJ.Polymorphisms of coagulation/fibrinolys INS genes:genes nvironment interactions and vascular risk[J].Prostaglandings Beukot Essent Fatty Acids.1997,57:473-477.
